Clinical trials: Polyarticular Juvenile Arthritis, open to volunteers
Polyarticular Course Juvenile Idiopathic Arthritis
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
This is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.
- Trial name
- GALAHOPPER (NCT07554495)
- Testing
- Filgotinib
- Where
- 14 sites in Belgium, Czechia and 7 more
- Volunteers
- 65 people
- Sponsor
- Alfasigma S.p.A.
Juvenile Idiopathic Arthritis, Tenosynovitis
Tenosynovitis in Polyarticular and Oligoarticular Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA) is a chronic condition that causes joint inflammation in children. In some cases, the inflammation also affects the protective sheath surrounding the tendons, a condition known as…
- Conditions
- Juvenile Idiopathic Arthritis, Tenosynovitis, Polyarticular Juvenile Idiopathic Arthritis, Oligoarticular Juvenile Idiopathic Arthritis
- Trial name
- NCT07553910
- Volunteers
- 106 people
- Sponsor
- Assiut University
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential…
- Trial name
- SMART-JIA (NCT06654882)
- Testing
- TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 400 people
- Sponsor
- Duke University
Healthy Volunteers
A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants
The purpose of this study is to assess the PK comparability and compare safety and tolerability of DRL_AB administered via an auto injector (AI) or prefilled syringe (PFS) in healthy male participants.
- Trial name
- NCT07744828
- Testing
- DRL_AB
- Where
- 3 sites in New Zealand
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA/CD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.
- Conditions
- Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
- Trial name
- NCT07184450
- Testing
- BCMA/CD70-targetd CAR-T
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis
Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness.
- Trial name
- KRXeljanzJIA (NCT05754710)
- Testing
- Xeljanz
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17.
- Trial name
- JUVE-X (NCT03773965)
- Testing
- Baricitinib
- Where
- 77 sites in Argentina, Australia and 18 more
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company